Investigating the Targeting Power to Brain Tissues of Intranasal Rasagiline Mesylate-Loaded Transferosomal In Situ Gel for Efficient Treatment of Parkinson’s Disease

Investigating the Targeting Power to Brain Tissues of Intranasal Rasagiline Mesylate-Loaded Transferosomal In Situ Gel for Efficient Treatment of Parkinson’s Disease

Rasagiline mesylate (RSM) is a hydrophilic drug with poor oral bioavailability (36%) because of hepatic first-pass metabolism. The present study focuses on delivering RSM directly to the brain through its inclusion within transferosomal in situ gel administered through the intranasal (IN) route. Tra...

Full description

Bibliographic Details
Main Authors: Hala N. ElShagea, Rana R. Makar, Alaa H. Salama, Nermeen A. Elkasabgy, Emad B. Basalious
Format: Article
Language:English
Published: MDPI AG 2023-02-01
Series:Pharmaceutics
Subjects:
drug delivery
nanotechnology
mucoadhesion
nose-to-brain delivery
brain kinetics
Online Access:https://www.mdpi.com/1999-4923/15/2/533

Internet

https://www.mdpi.com/1999-4923/15/2/533

Similar Items